PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
5.92%
Revenue growth of 5.92% vs. zero growth in Medical - Pharmaceuticals. Walter Schloss might still want to see if it can translate into profits.
5.52%
Gross profit growth of 5.52% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight advantage that could be built upon.
29.29%
Positive EBIT growth while Medical - Pharmaceuticals median is negative. Peter Lynch might see a strong competitive advantage in operations.
35.99%
Operating income growth of 35.99% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage that can expand.
30.23%
Net income growth of 30.23% while Medical - Pharmaceuticals median is zero. Walter Schloss might see potential if moderate gains can keep rising.
30.21%
EPS growth of 30.21% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight edge that could compound over time.
30.21%
Diluted EPS growth of 30.21% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight edge that could improve over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
57.27%
10Y CAGR of 57.27% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight advantage that can compound over very long horizons.
-14.00%
Negative 5Y CAGR while Medical - Pharmaceuticals median is 16.91%. Seth Klarman would see if others are at least growing moderately, indicating a firm-specific problem.
37.58%
3Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 4.20%. Joel Greenblatt might see a short-term competitive advantage at play.
100.00%
OCF/share CAGR of 100.00% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest edge that can add up if momentum improves.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
204.55%
Net income/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 15.52% over a decade. Joel Greenblatt might see a standout compounder of earnings.
1.06%
Below 50% of Medical - Pharmaceuticals median. Jim Chanos would suspect deeper problems limiting mid-term profit potential.
46.13%
3Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 14.29%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
174.00%
Equity/share CAGR of 174.00% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
20.89%
5Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 5.05%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
67.68%
3Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 17.69%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-20.00%
AR shrinking while Medical - Pharmaceuticals median grows. Seth Klarman sees potential advantage unless it signals declining demand.
0.71%
Inventory growth of 0.71% while Medical - Pharmaceuticals median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
0.86%
Asset growth near Medical - Pharmaceuticals median. Charlie Munger attributes it to a typical industry cycle of capital investment.
3.21%
BV/share growth exceeding 1.5x Medical - Pharmaceuticals median. Joel Greenblatt checks if consistent ROE or undervalued buybacks fuel this advantage.
20.57%
Debt growth of 20.57% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest difference that matters if interest coverage is tight.
No Data
No Data available this quarter, please select a different quarter.
-0.12%
SG&A decline while Medical - Pharmaceuticals grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.